52 completed, 25 recruiting, 9 unknown, 6 terminated. 20 Phase 3, 12 Phase 2, 8 Not applicable, 6 Phase 1, 4 Phase 4.
Follow von Willebrand Diseases: new trials by email Literature Review of von Willebrand Diseases trials Research Report on von Willebrand Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| HMBeacon: A Phase 2 Study to Evaluate ALN-6400 in Adult and Adolescent Female Patients With VWD and HMB ALN-6400 - Von Willebrand Disease (VWD), Heavy Menstrual Bleeding (HMB) | Phase 2 | Recruiting | Alnylam Pharmaceuticals | 24 | 2026-07-30 | 2026-09-18 |
| Algorithm-based Management to Reduce the Recurrence of GI Bleeding and Severe Epistaxis in Von Willebrand Disease Optimized management, Standard of care management - Von Willebrand Disease (VWD) | Not applicable | Recruiting | University Hospital, Lille | 66 | 2026-03-10 | 2026-05-18 |
| Clinical Spectrum and Management of Von Willebrand Disease Among Children in Assiut Governorate Tranexamic Acid, Von Willebrand Factor-Containing Concentrates - Von Willebrand Disease (VWD), Inherited Bleeding Disorders in Children | Not yet recruiting | Assiut University | 25 | 2026-03-01 | 2026-02-13 | |
| An Observational Study of Vonicog Alfa (rVWF) in Pediatric Participants With Von Willebrand Disease (vWD) vonicog alfa (rVWF) - Von Willebrand Disease (vWD) | Recruiting | Takeda | 13 | 2026-02-19 | 2026-02-23 | |
| External Multicenter Validation of the APTTO Model for Prolonged APTT Using Clot Waveform Analysis Clot waveform analysis-based risk stratification (APTTO models) - Coagulation Disorder, Blood, Prolonged APTT | Recruiting | Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz | 1500 | 2026-01-13 | 2026-09-11 | |
| A Phase II Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of SR604 Injection in Patients With Von Willebrand Disease SR604 - Von Willebrand Disease (VWD) | Phase 2 | Recruiting | Shanghai RAAS Blood Products Co., Ltd. | 24 | 2025-11-26 | 2026-06-11 |
| Study to Evaluate Subcutaneous (SC) VGA039 in Patients With Von Willebrand Disease (VWD) VGA039 - Von Willebrand Disease (VWD) | Phase 3 | Recruiting | Vega Therapeutics, Inc | 60 | 2025-10-15 | 2026-09-14 |
| A Study of Recombinant Von Willebrand Factor (rVWF) in Chinese Participants With Von Willebrand Disease (vWD) VONVENDI, ADVATE - Von Willebrand Disease (VWD) | Phase 3 | Recruiting | Takeda | 20 | 2025-10-13 | 2026-01-08 |
| The Bleeding Assessment Tool (BAT) Bleeding Disorder, Von Willebrand Disease (VWD) | Active not recruiting | Children's Hospital Medical Center, Cincinnati | 1000 | 2025-10-09 | 2026-04-30 | |
| Heavy Menstrual Bleeding Progestin Treatment in Bleeding Disorders Study Levonorgestrel Intrauterine System, Norethindrone Acetate - Heavy Menstrual Bleeding, Bleeding Disorder | Recruiting | Oregon Health and Science University | 300 | 2025-09-24 | 2025-12-17 | |
| Efficacy and Safety of BT200 (Rondaptivon Pegol) in Patients With Type 2B Von Willebrand Disease BT200, Placebo - Von Willebrand Disease (VWD), Type 2 | Phase 2 | Recruiting | Medical University of Vienna | 6 | 2025-08-14 | 2025-12-09 |
| A Study to Assess the Efficacy and Safety of Emicizumab in Participants With Type 3 Von Willebrand Disease Emicizumab, von Willebrand Factor (VWF) Concentrates, Factor VIII (FVIII) Concentrates - Von Willebrand Disease, Type 3 | Phase 3 | Recruiting | Hoffmann-La Roche | 75 | 2025-06-27 | 2026-10-09 |
| An Observational Study of Participants With Type 3 Von Willebrand Disease on Prophylactic Standard-of-Care Treatment Von Willebrand Factor Concentrates, Von Willebrand Factor Concentrates and Factor VIII Concentrates, Factor VIII Concentrates - Von Willebrand Disease, Type 3 | Active not recruiting | Hoffmann-La Roche | 44 | 2025-04-29 | 2026-08-10 | |
| A Study Assessing HMB-002 in Participants With Von Willebrand Disease HMB-002 (Part A), HMB-002 (Part B), HMB-002 with Concomitant Factor Concentrate (Part C) (Not Applicable in US) - Von Willebrand Disease (VWD), Von Willebrand Disease (VWD), Type 1 | Phase 1 / Phase 2 | Recruiting | Hemab ApS | 108 | 2025-02-06 | 2026-06-30 |
| A Study of Vonicog Alfa (rVWF) in Children With Severe Von Willebrand Disease (vWD) Vonicog Alfa, ADVATE - Von Willebrand Disease (VWD) | Phase 3 | Recruiting | Takeda | 24 | 2024-11-06 | 2026-09-09 |
| ATHNdataset Registry Hemophilia, Thrombosis | Recruiting | American Thrombosis and Hemostasis Network | 200000 | 2024-10-25 | 2026-04-21 | |
| A Pilot Crossover Trial of Prophylactic Wilate Compared to Placebo for Heavy Menstrual Bleeding in Patients With VWD Lyophilized concentrate of human coagulation von Willebrand Factor and factor VIII, Placebo - Von Willebrand Diseases | Phase 3 | Recruiting | Unity Health Toronto | 20 | 2024-10-21 | 2026-10-14 |
| A Study of Bleeding and Treatment in Participants With Von Willebrand Disease Clinical outcomes of patients with VWD, Type 1, Clinical outcomes of patients with VWD, Type 2A, Type 2M, Type 2N, or Type 3 - Von Willebrand Disease (VWD), Von Willebrand Disease (VWD), Type 1 | Recruiting | Hemab ApS | 200 | 2024-08-30 | 2026-04-21 | |
| T-TAS® wS Method Comparison T-TAS PL Assay - Antiplatelet Therapy, Healthy Donors | Completed | Hikari Dx, Inc. | 115 | 2024-08-21 | 2025-07-28 | |
| Impact of Von Willebrand Factor and Its Multimers on Angiogenesis no intervention - Von Willebrand Diseases | Completed | Nantes University Hospital | 109 | 2024-02-07 | 2026-09-24 |
Showing 20 of 102. Sign in to see all of them.
Hemophilia A (16) · Hemostatic Disorders (10) · Menorrhagia (9) · von Willebrand Disease, Type 3 (8) · Hemophilia B (7) · Hemorrhage (7) · Hematologic Diseases (6) · Blood Coagulation Disorders (4) · Anemia, Sickle Cell (3) · Blood Platelet Disorders (3) · Disease (3) · Thrombosis (3) · Angiodysplasia (2) · Gastrointestinal Hemorrhage (2)
Coagulation Protein Disorders (102) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (102) · Genetic Diseases, Inborn (102) · Hemic and Lymphatic Diseases (102) · Hemorrhagic Disorders (102) · Blood Coagulation Disorders, Inherited (101) · Blood Coagulation Disorders (98) · Hematologic Diseases (96) · Blood Platelet Disorders (93) · Pathologic Processes (25) · Pathological Conditions, Signs and Symptoms (25) · Cardiovascular Diseases (15) · Hemorrhage (14) · Vascular Diseases (13) · Female Urogenital Diseases and Pregnancy Complications (12)
Factor VIII (12) · von Willebrand Factor (11) · Tranexamic Acid (5) · F8 protein, human (4) · Interleukin-11 (4) · oprelvekin (4) · optivate (3) · Blood Specimen Collection (2) · emicizumab (2) · ARC 1779 (1) · BIVV001 (1) · Deamino Arginine Vasopressin (1) · Exercise (1) · Exome (1) · Levonorgestrel (1)
Takeda (8) · CSL Behring (7) · Baxalta now part of Shire (5) · Octapharma (5) · Assiut University (4) · Nantes University Hospital (4) · University Hospital, Lille (4) · American Thrombosis and Hemostasis Network (3) · Bio Products Laboratory (3) · Margaret Ragni (3) · Erasmus Medical Center (2) · Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico (2) · Hemab ApS (2) · Hikari Dx, Inc. (2) · Hoffmann-La Roche (2)
United States (43) · France (23) · United Kingdom (20) · Germany (18) · Italy (15) · Spain (12) · Canada (11) · Netherlands (11) · Austria (10) · Russia (10) · Sweden (8) · Ukraine (8) · Poland (7) · Australia (6) · Belgium (5)
Margaret V. Ragni, MD, MPH (3) · Frank WG Leebeek, MD, PhD (2) · Karina Meijer, MD, PhD (2) · Margaret V Ragni, MD, MPH (2) · Allison Wheeler (1) · Angela Weyand, MD (1) · Antoine Rauch, MD,PhD (1) · Arja de Goede-Bolder, MD (1) · Augusto B. Federici, MD (1)
PMID 38237075, PMID 16247740, PMID 16359502, PMID 16634745, PMID 16634746, PMID 16889557, PMID 16985174, PMID 17059476, PMID 17488667, PMID 18315556, PMID 18344424, PMID 19277422, PMID 19566550, PMID 19786936, PMID 20801902, PMID 21199188, PMID 21251206, PMID 21833452, PMID 22102193, PMID 22197721, PMID 22507569, PMID 22534727, PMID 22823000, PMID 23231463, PMID 23238591, PMID 23349392, PMID 23633542, PMID 23777763, PMID 25077350, PMID 25113304, PMID 25381842, PMID 25688461, PMID 2584182, PMID 26239086, PMID 26245874, PMID 26862110, PMID 28916584, PMID 28971901, PMID 29370241, PMID 29924855, PMID 30361419, PMID 30586737, PMID 31041796, PMID 31315600, PMID 32135566, PMID 3492222, PMID 35142618, PMID 35439298, PMID 35772170, PMID 36108308
2009 (2), 2016 (2), 2023 (2), 2008 (1), 2014 (1), 2018 (1), 2025 (1), U01HL133815 (1)